An early innate response underlies severe influenza-induced exacerbations of asthma in a novel steroid-insensitive and anti-IL-5-responsive mouse model

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 72, Issue 5, 2017, Pages 737-753

  Ravanetti, L ^a   Dijkhuis, A ^a   Sabogal Pineros, Y S ^a   Bal, S M ^a   Dierdorp, B S ^a   Dekker, T ^a   Logiantara, A ^a   Adcock, I M ^b   Rao, N L ^c   Boon, L ^d   Villetti, G ^e   Sterk, P J ^a   Facchinetti, F ^e   Lutter, R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d BIOCEROS   (Netherlands)

^e CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

animal models; asthma; basic immunology; innate immunity; virus

Indexed keywords

FLUTICASONE PROPIONATE; INTERLEUKIN 5 ANTIBODY; PREDNISONE; ALLERGEN; AMPHIREGULIN; ANTIASTHMATIC AGENT; CYTOKINE; FLUTICASONE; INTERLEUKIN 5; MONOCLONAL ANTIBODY; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DERMATOPHAGOIDES; DISEASE EXACERBATION; EOSINOPHIL; INFLUENZA; INNATE IMMUNITY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOPSY; BIOSYNTHESIS; COMPLICATION; DISEASE MODEL; DRUG TOLERANCE; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS; METABOLISM; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PYROGLYPHIDAE; VIROLOGY; VIRUS LOAD;

ALLERGENS; AMPHIREGULIN; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOPSY; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG TOLERANCE; EOSINOPHILS; FLUTICASONE; IMMUNITY, INNATE; IMMUNIZATION; INFLUENZA A VIRUS; INTERLEUKIN-5; MALE; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PYROGLYPHIDAE; STEROIDS; VIRAL LOAD;

EID: 85001115556     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.13057     Document Type: Article

References (43)

1. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011;128:1165–1174.
2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–73.
3. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–478.
4. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009;39:193–202.
5. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Br Med J 1995;310:1225–1229.
6. Mahut B, Refabert L, Marchac V, Iniguez JL, Aubertin G, Tamalet A et al. Influenza-like illness responsible for severe exacerbations in asthmatic children during H1N1 pandemic: a survey before vaccination. J Asthma 2011;48:224–227.
7. Sandrock CE, Norris A. Infection in severe asthma exacerbations and critical asthma syndrome. Clin Rev Allergy Immunol 2015;48:104–113.
8. Matsuse H, Tsuchida T, Fukahori S, Kawano T, Tomari S, Matsuo N et al. Differential airway inflammatory responses in asthma exacerbations induced by respiratory syncytial virus and influenza virus a. Int Arch Allergy Immunol 2013;161:378–382.
9. Fleming DM, Pannell RS, Elliot AJ, Cross KW. Respiratory illness associated with influenza and respiratory syncytial virus infection. Arch Dis Child 2005;90:741–746.
10. Zhu J, Message SD, Qiu Y, Mallia P, Kebadze T, Contoli M et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest 2014;145:1219–1229.
11. Singh AM, Busse WW. Asthma exacerbations. 2: aetiology. Thorax 2006;61:809–816.
12. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
13. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
14. Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med 2004;169:378–385.
15. Ulrich K, Hincks JS, Walsh R, Wetterstrand EMC, Fidock MD, Sreckovic S et al. Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model. Pulm Pharmacol Ther 2008;21:637–647.
16. Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 2009;4:e5538.
17. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999;103:175–183.
18. van der Sluijs KF, van Elden L, Nijhuis M, Schuurman R, Florquin S, Jansen HM et al. Toll-like receptor 4 is not involved in host defense against respiratory tract infection with Sendai virus. Immunol Lett 2003;89:201–206.
19. FitzGerald JM, Gibson PG. Asthma exacerbations. 4: prevention. Thorax 2006;61:992–999.
20. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–984.
21. Pavord ID, Haldar P, Bradding P, Wardlaw AJ. Mepolizumab in refractory eosinophilic asthma. Thorax 2010;65:370.
22. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011;12:1045–1054.
23. Enomoto Y, Orihara K, Takamasu T, Matsuda A, Gon Y, Saito H et al. Tissue remodeling induced by hypersecreted epidermal growth factor and amphiregulin in the airway after an acute asthma attack. J Allergy Clin Immunol 2009;124:913–920.
24. Pulendran B, Artis D. New paradigms in type 2 immunity. Science 2012;337:431–435.
25. Aldington S, Beasley R. Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital. Thorax 2007;62:447–458.
26. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J et al. IL-33–dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 2014;190:1373–1382.
27. Johnston SL. Innate immunity in the pathogenesis of virus-induced asthma exacerbations. Proc Am Thorac Soc 2007;4:267–270.
28. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 2015;16:609–617.
29. Schwantes EA, Manthei DM, Denlinger LC, Evans MD, Gern JE, Jarjour NN et al. Interferon gene expression in sputum cells correlates with the Asthma Index Score during virus-induced exacerbations. Clin Exp Allergy 2014;44:813–821.
30. Dyer KD, Czapiga M, Foster B, Foster PS, Kang EM, Lappas CM et al. Eosinophils from lineage-ablated Delta dblGATA bone marrow progenitors: the dblGATA enhancer in the promoter of GATA-1 is not essential for differentiation ex vivo. J Immunol 2007;179:1693–1699.
31. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709–750.
32. Percopo CM, Dyer KD, Karpe KA, Domachowske JB, Rosenberg HF. Eosinophils and respiratory virus infection: a dual-standard curve qRT-PCR-based method for determining virus recovery from mouse lung tissue. Methods Mol Biol 2014;1178:257–266.
33. Fukumoto J, Harada C, Kawaguchi T, Suetsugu S, Maeyama T, Inoshima I et al. Amphiregulin attenuates bleomycin-induced pneumopathy in mice. Am J Physiol Lung Cell Mol Physiol 2010;298:L131–L138.
34. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008;14:199–204.
35. Kumar RK, Herbert C, Foster PS. The “classical” ovalbumin challenge model of asthma in mice. Curr Drug Targets 2008;9:485–494.
36. Nials AT, Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech 2008;1:213–220.
37. Jungsuwadee P, Benkovszky M, Dekan G, Stingl G, Epstein MM. Repeated aerosol allergen exposure suppresses inflammation in B-cell-deficient mice with established allergic asthma. Int Arch Allergy Immunol 2004;133:40–48.
38. Nguyen TH, Maltby S, Simpson JL, Eyers F, Baines KJ, Gibson PG et al. TNF-alpha and macrophages are critical for respiratory syncytial virus-induced exacerbations in a mouse model of allergic airways disease. J Immunol 2016;196:3547–3558.
39. Hasegawa S, Wakiguchi H, Okada S, Gui Kang Y, Fujii N, Hasegawa M et al. Cytokine profile of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during seasonal H1N1 infection. Cytokine 2014;69:206–210.
40. Clarke DL, Davis NH, Majithiya JB, Piper SC, Lewis A, Sleeman MA et al. Development of a mouse model mimicking key aspects of a viral asthma exacerbation. Clin Sci (Lond) 2014;126:567–580.
41. De Alba J, Otal R, Calama E, Domenech A, Prats N, Gozzard N et al. Double-stranded RNA evokes exacerbation in a mouse model of corticosteroid refractory asthma. Clin Sci (Lond) 2015;129:973–987.
42. Mahmutovic Persson I, Akbarshahi H, Menzel M, Brandelius A, Uller L. Increased expression of upstream TH2-cytokines in a mouse model of viral-induced asthma exacerbation. J Transl Med 2016;14:52.
43. Verheijden KA, Henricks PA, Redegeld FA, Garssen J, Folkerts G. Measurement of airway function using invasive and non-invasive methods in mild and severe models for allergic airway inflammation in mice. Front Pharmacol 2014;5:190.